Hereditary Cancer panel - 23 gene panel (APC, ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM , MLH1, MSH2, MSH6, MUTYH, PALB2, POLD1, POLE, PTEN, RAD51C, RAD51D, SMAD4, STK11, TP53) - (B)

Test Code: MD

Description:  Full gene sequence analysis including the entire coding region and flanking intronic DNA (+/- 10 bp) is performed on the following 23 genes: APC, ATM, BARD1, BMPR1A (only sequencing), BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM (only deletion analysis), MLH1, MSH2, MSH6, MUTYH, PALB2, POLD1, POLE, PTEN, RAD51C, RAD51D, SMAD4, STK11, TP53

Test Indications: Ordering clinician should check clinical syndrome suspected, that is: Hereditary breast and ovarian cancer syndromes, gastrointestinal/Lynch Syndrome panel or other.
 
Testing for single gene analysis is available by request. Please provide clinical indication and family history.

Note, non-coding regions such as promoters, deep intronic regions, and untranslated regions are not usually examined by this analysis.

Ordering restricted to: Medical Genetics
Recommendations: Testing is limited to Medical Genetics.
 

_SH Hereditary Cancer Molecular Requisition (R250-10-10)

Within 12 Weeks

Routine TAT is 12 weeks. STAT TAT 4-6 weeks may be requested following laboratory consultation

HEREDITARY BREAST AND OVARIAN CANCER SYNDROME, ETHNIC SPECIFIC MUTATIONS - BRCA1, BRCA2 GENES - (B)

HEREDITARY BREAST CANCER

FAMILIAL ADENOMATOUS POLYPOSIS (FAP) - APC GENE - (B)

HEREDITARY BREAST AND OVARIAN CANCER PANEL (BRCA1, BRCA2, PTEN, TP53, PALB2, STK11, MLH1, MSH2, MSH6, EPCAM) - (B)

FAMILY SPECIFIC CANCER GENE VARIANT ANALYSIS - (B)

LYNCH POLYPOSIS GENE PANEL (MLH1, MSH2, MSH6, EPCAM, APC, MUTYH, STK11, PTEN, BMPR1A, SMAD4, POLD1 AND POLE) - (B)

Lynch syndrome- MLH1 gene Mennonite variant (c.2141G>A, p.Trp714Ter) - (B)

BRCA1 & BRCA2 GENE ANALYSIS - (B)

Interpretation & Assay Interferences: An interpretive report will be sent.